Brian Stauffer
Concepts (477)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelium, Vascular | 42 | 2026 | 965 | 3.220 |
Why?
| | Hypertension | 12 | 2023 | 1264 | 2.390 |
Why?
| | Endothelin-1 | 18 | 2026 | 184 | 2.070 |
Why?
| | Vasodilation | 27 | 2025 | 523 | 1.950 |
Why?
| | Cardiomyopathy, Dilated | 13 | 2025 | 359 | 1.880 |
Why?
| | Endothelial Cells | 14 | 2026 | 870 | 1.470 |
Why?
| | Cell-Derived Microparticles | 8 | 2025 | 75 | 1.420 |
Why?
| | Fibrinolysis | 11 | 2025 | 162 | 1.360 |
Why?
| | Heart Ventricles | 11 | 2021 | 760 | 1.340 |
Why?
| | Resistance Training | 2 | 2024 | 182 | 1.300 |
Why?
| | Myocytes, Cardiac | 10 | 2025 | 556 | 1.260 |
Why?
| | Metoprolol | 2 | 2022 | 26 | 1.250 |
Why?
| | Vasoconstriction | 13 | 2025 | 217 | 1.220 |
Why?
| | Obesity | 22 | 2026 | 3082 | 1.160 |
Why?
| | Myocardium | 12 | 2017 | 939 | 1.040 |
Why?
| | Aging | 17 | 2026 | 1966 | 1.030 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 61 | 0.970 |
Why?
| | MicroRNAs | 11 | 2025 | 701 | 0.970 |
Why?
| | Blood Pressure | 13 | 2022 | 1769 | 0.950 |
Why?
| | Tissue Plasminogen Activator | 14 | 2026 | 244 | 0.940 |
Why?
| | Vasodilator Agents | 22 | 2025 | 331 | 0.890 |
Why?
| | Nebivolol | 3 | 2022 | 9 | 0.840 |
Why?
| | Heart Failure | 10 | 2023 | 2323 | 0.820 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 72 | 0.820 |
Why?
| | Testosterone | 5 | 2026 | 419 | 0.770 |
Why?
| | Forearm | 17 | 2025 | 140 | 0.750 |
Why?
| | Postmenopause | 8 | 2023 | 391 | 0.740 |
Why?
| | Qigong | 1 | 2022 | 2 | 0.730 |
Why?
| | Nitric Oxide | 10 | 2026 | 897 | 0.720 |
Why?
| | Exercise | 12 | 2023 | 2201 | 0.710 |
Why?
| | Overweight | 9 | 2019 | 609 | 0.710 |
Why?
| | Isoproterenol | 4 | 2018 | 97 | 0.700 |
Why?
| | Middle Aged | 78 | 2026 | 35928 | 0.680 |
Why?
| | Male | 97 | 2026 | 72406 | 0.670 |
Why?
| | C-Reactive Protein | 6 | 2015 | 417 | 0.670 |
Why?
| | Cardiolipins | 3 | 2025 | 82 | 0.610 |
Why?
| | Mendelian Randomization Analysis | 1 | 2019 | 55 | 0.600 |
Why?
| | Extracellular Vesicles | 3 | 2026 | 171 | 0.590 |
Why?
| | Sleep Deprivation | 5 | 2021 | 206 | 0.590 |
Why?
| | Troponin I | 1 | 2019 | 72 | 0.580 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2024 | 1721 | 0.580 |
Why?
| | Connexin 43 | 3 | 2025 | 36 | 0.580 |
Why?
| | Humans | 114 | 2026 | 144957 | 0.580 |
Why?
| | Heart Diseases | 3 | 2013 | 350 | 0.560 |
Why?
| | Meta-Analysis as Topic | 1 | 2019 | 174 | 0.560 |
Why?
| | Mitochondria, Heart | 3 | 2020 | 102 | 0.560 |
Why?
| | Regional Blood Flow | 19 | 2025 | 514 | 0.550 |
Why?
| | Coronary Disease | 2 | 2019 | 386 | 0.550 |
Why?
| | Female | 81 | 2026 | 78376 | 0.550 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 2 | 2017 | 9 | 0.540 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 511 | 0.520 |
Why?
| | Calcium | 4 | 2021 | 1184 | 0.520 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 541 | 0.520 |
Why?
| | Vasoconstrictor Agents | 7 | 2023 | 144 | 0.510 |
Why?
| | Rest | 3 | 2022 | 124 | 0.510 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 9 | 0.510 |
Why?
| | Shock, Cardiogenic | 1 | 2017 | 64 | 0.490 |
Why?
| | Acetylcholine | 16 | 2025 | 206 | 0.490 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 230 | 0.490 |
Why?
| | Epoprostenol | 1 | 2017 | 131 | 0.480 |
Why?
| | Heart Arrest | 1 | 2020 | 407 | 0.470 |
Why?
| | Aged | 42 | 2026 | 25947 | 0.460 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 361 | 0.450 |
Why?
| | Sex Characteristics | 6 | 2017 | 791 | 0.450 |
Why?
| | Heart Rate | 2 | 2022 | 855 | 0.450 |
Why?
| | YY1 Transcription Factor | 1 | 2015 | 25 | 0.450 |
Why?
| | Cardiovascular Diseases | 10 | 2024 | 2171 | 0.440 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.440 |
Why?
| | Microvessels | 2 | 2026 | 99 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.440 |
Why?
| | Muscle Tonus | 3 | 2010 | 24 | 0.440 |
Why?
| | Ventricular Dysfunction, Right | 2 | 2017 | 248 | 0.430 |
Why?
| | Phosphorylation | 6 | 2021 | 1733 | 0.430 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1209 | 0.420 |
Why?
| | Adult | 47 | 2026 | 40506 | 0.420 |
Why?
| | Age Factors | 14 | 2026 | 3335 | 0.410 |
Why?
| | Circulating MicroRNA | 3 | 2019 | 26 | 0.410 |
Why?
| | Cardiomegaly | 1 | 2015 | 174 | 0.410 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2010 | 452 | 0.390 |
Why?
| | Vasomotor System | 2 | 2025 | 46 | 0.380 |
Why?
| | Physical Fitness | 2 | 2024 | 209 | 0.360 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 275 | 0.360 |
Why?
| | Gene Expression Regulation | 5 | 2016 | 2609 | 0.350 |
Why?
| | Transcriptome | 2 | 2021 | 1046 | 0.350 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.340 |
Why?
| | Heart | 6 | 2021 | 636 | 0.340 |
Why?
| | Heart-Assist Devices | 2 | 2016 | 567 | 0.340 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 60 | 0.330 |
Why?
| | Atherosclerosis | 2 | 2019 | 409 | 0.330 |
Why?
| | Spinal Cord Injuries | 2 | 2025 | 241 | 0.330 |
Why?
| | Sleep | 5 | 2021 | 901 | 0.320 |
Why?
| | Stroke | 1 | 2019 | 1258 | 0.310 |
Why?
| | Health | 1 | 2010 | 81 | 0.310 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 56 | 0.310 |
Why?
| | Body Composition | 7 | 2023 | 706 | 0.300 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 276 | 0.300 |
Why?
| | Disease | 1 | 2010 | 98 | 0.300 |
Why?
| | Biomarkers | 13 | 2025 | 4275 | 0.300 |
Why?
| | beta 2-Microglobulin | 1 | 2008 | 47 | 0.290 |
Why?
| | Mitochondria | 2 | 2026 | 984 | 0.290 |
Why?
| | Oligopeptides | 3 | 2025 | 269 | 0.280 |
Why?
| | Child, Preschool | 14 | 2025 | 11799 | 0.280 |
Why?
| | Nitroprusside | 13 | 2016 | 72 | 0.280 |
Why?
| | Physical Endurance | 3 | 2013 | 278 | 0.280 |
Why?
| | Prehypertension | 3 | 2014 | 27 | 0.280 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 354 | 0.270 |
Why?
| | Cells, Cultured | 7 | 2026 | 4155 | 0.270 |
Why?
| | Gender Identity | 2 | 2006 | 121 | 0.270 |
Why?
| | Soybean Proteins | 2 | 2014 | 14 | 0.260 |
Why?
| | Child | 20 | 2025 | 22657 | 0.260 |
Why?
| | Brachial Artery | 3 | 2025 | 206 | 0.260 |
Why?
| | Estrogen Replacement Therapy | 3 | 2013 | 144 | 0.250 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 914 | 0.250 |
Why?
| | RNA, Messenger | 7 | 2021 | 2832 | 0.240 |
Why?
| | Reference Values | 4 | 2016 | 798 | 0.230 |
Why?
| | Nitric Oxide Synthase Type III | 5 | 2026 | 204 | 0.230 |
Why?
| | Sirtuins | 1 | 2026 | 50 | 0.230 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2016 | 53 | 0.230 |
Why?
| | Case-Control Studies | 12 | 2025 | 3608 | 0.220 |
Why?
| | Hypoplastic Left Heart Syndrome | 3 | 2017 | 120 | 0.220 |
Why?
| | Oxidative Stress | 7 | 2026 | 1339 | 0.220 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 685 | 0.220 |
Why?
| | Apoptosis | 7 | 2025 | 2430 | 0.220 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2584 | 0.220 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 73 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2017 | 2032 | 0.210 |
Why?
| | Vascular Stiffness | 2 | 2024 | 487 | 0.210 |
Why?
| | Hypogonadism | 1 | 2024 | 90 | 0.200 |
Why?
| | Brain | 2 | 2026 | 2941 | 0.200 |
Why?
| | Disease Models, Animal | 5 | 2018 | 4569 | 0.200 |
Why?
| | Analysis of Variance | 6 | 2016 | 1311 | 0.200 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 93 | 0.190 |
Why?
| | Genomics | 1 | 2008 | 836 | 0.190 |
Why?
| | Bradykinin | 8 | 2025 | 48 | 0.190 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 62 | 0.190 |
Why?
| | Body Weight | 4 | 2023 | 978 | 0.190 |
Why?
| | Adaptation, Physiological | 3 | 2014 | 570 | 0.190 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 61 | 0.190 |
Why?
| | Dietary Fats | 2 | 2015 | 315 | 0.180 |
Why?
| | Animals | 18 | 2025 | 38109 | 0.180 |
Why?
| | Systole | 2 | 2021 | 178 | 0.180 |
Why?
| | Baroreflex | 1 | 2022 | 57 | 0.180 |
Why?
| | Down-Regulation | 3 | 2025 | 627 | 0.180 |
Why?
| | Cell Movement | 4 | 2014 | 965 | 0.180 |
Why?
| | Calcium-Binding Proteins | 2 | 2021 | 220 | 0.180 |
Why?
| | Plethysmography | 6 | 2022 | 109 | 0.170 |
Why?
| | Proteomics | 1 | 2008 | 1195 | 0.170 |
Why?
| | Myocardial Contraction | 3 | 2019 | 298 | 0.170 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2011 | 145 | 0.170 |
Why?
| | Focal Adhesions | 1 | 2021 | 47 | 0.170 |
Why?
| | Adolescent | 11 | 2026 | 22453 | 0.170 |
Why?
| | Cross-Sectional Studies | 13 | 2026 | 5872 | 0.170 |
Why?
| | Hemodynamics | 2 | 2021 | 1121 | 0.170 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2021 | 64 | 0.170 |
Why?
| | RNA-Binding Proteins | 1 | 2025 | 464 | 0.170 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2011 | 49 | 0.170 |
Why?
| | Vascular Diseases | 1 | 2023 | 251 | 0.170 |
Why?
| | Milrinone | 1 | 2021 | 26 | 0.160 |
Why?
| | Serum | 2 | 2018 | 59 | 0.160 |
Why?
| | Young Adult | 14 | 2026 | 14126 | 0.160 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2022 | 250 | 0.160 |
Why?
| | Hyperemia | 1 | 2020 | 49 | 0.160 |
Why?
| | Estrogens | 3 | 2012 | 380 | 0.160 |
Why?
| | Inflammation Mediators | 2 | 2018 | 509 | 0.150 |
Why?
| | Stem Cells | 3 | 2010 | 627 | 0.150 |
Why?
| | Heart Transplantation | 3 | 2015 | 736 | 0.150 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 26 | 0.150 |
Why?
| | Time Factors | 7 | 2021 | 7183 | 0.150 |
Why?
| | Physical Exertion | 2 | 2014 | 207 | 0.150 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 187 | 0.150 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 60 | 0.150 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 23 | 0.140 |
Why?
| | Flecainide | 1 | 2018 | 8 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 415 | 0.140 |
Why?
| | Rats | 5 | 2025 | 5614 | 0.140 |
Why?
| | Endothelium | 3 | 2020 | 119 | 0.140 |
Why?
| | Guinea Pigs | 1 | 2018 | 159 | 0.140 |
Why?
| | Fibrosis | 6 | 2023 | 548 | 0.140 |
Why?
| | Telomere | 3 | 2010 | 288 | 0.140 |
Why?
| | Up-Regulation | 3 | 2018 | 852 | 0.140 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 72 | 0.140 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 137 | 0.130 |
Why?
| | HIV | 1 | 2019 | 250 | 0.130 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 142 | 0.130 |
Why?
| | Blood Flow Velocity | 4 | 2022 | 413 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Extracellular Matrix | 1 | 2021 | 553 | 0.130 |
Why?
| | Walking | 1 | 2022 | 545 | 0.130 |
Why?
| | Kearns-Sayre Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
| | Coronary Occlusion | 1 | 2017 | 20 | 0.130 |
Why?
| | Mitochondrial Myopathies | 1 | 2016 | 10 | 0.130 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 36 | 0.130 |
Why?
| | Blotting, Western | 2 | 2016 | 1187 | 0.130 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 57 | 0.130 |
Why?
| | Caspase 3 | 4 | 2011 | 238 | 0.120 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 63 | 0.120 |
Why?
| | Sampling Studies | 1 | 2016 | 99 | 0.120 |
Why?
| | Double-Blind Method | 3 | 2017 | 2029 | 0.120 |
Why?
| | Body Mass Index | 7 | 2017 | 2438 | 0.120 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 560 | 0.120 |
Why?
| | Behavior Therapy | 1 | 2019 | 299 | 0.120 |
Why?
| | Prognosis | 6 | 2018 | 4293 | 0.120 |
Why?
| | Specimen Handling | 1 | 2018 | 186 | 0.120 |
Why?
| | Oxidation-Reduction | 2 | 2018 | 1087 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 225 | 0.120 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 297 | 0.120 |
Why?
| | Infant | 6 | 2017 | 10039 | 0.120 |
Why?
| | Exosomes | 1 | 2017 | 104 | 0.120 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 235 | 0.120 |
Why?
| | Administration, Inhalation | 1 | 2017 | 575 | 0.110 |
Why?
| | Collagen Type III | 1 | 2015 | 18 | 0.110 |
Why?
| | Carrier Proteins | 1 | 2019 | 737 | 0.110 |
Why?
| | Myosin Heavy Chains | 5 | 2014 | 185 | 0.110 |
Why?
| | Weight Loss | 2 | 2019 | 837 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2020 | 11695 | 0.110 |
Why?
| | Diet | 2 | 2014 | 1275 | 0.110 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 144 | 0.110 |
Why?
| | Action Potentials | 1 | 2018 | 507 | 0.110 |
Why?
| | Mice | 9 | 2015 | 18365 | 0.110 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2014 | 14 | 0.110 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 29 | 0.110 |
Why?
| | Cytoskeletal Proteins | 1 | 2015 | 156 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2015 | 136 | 0.100 |
Why?
| | Linear Models | 1 | 2016 | 854 | 0.100 |
Why?
| | Gene Expression | 3 | 2017 | 1490 | 0.100 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 48 | 0.100 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 20 | 0.100 |
Why?
| | Ascorbic Acid | 2 | 2021 | 180 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1990 | 0.100 |
Why?
| | Plasminogen Activator Inhibitor 1 | 4 | 2023 | 84 | 0.100 |
Why?
| | Diet, High-Fat | 1 | 2015 | 261 | 0.100 |
Why?
| | Tissue Donors | 1 | 2016 | 424 | 0.100 |
Why?
| | Lipids | 3 | 2009 | 710 | 0.100 |
Why?
| | Adiposity | 3 | 2016 | 543 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 171 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2015 | 2185 | 0.090 |
Why?
| | Phytoestrogens | 1 | 2012 | 17 | 0.090 |
Why?
| | Interleukin-6 | 4 | 2022 | 780 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 35 | 0.090 |
Why?
| | Animals, Newborn | 3 | 2021 | 902 | 0.090 |
Why?
| | Piperidines | 2 | 2013 | 217 | 0.090 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 263 | 0.090 |
Why?
| | Cytokines | 2 | 2010 | 2065 | 0.090 |
Why?
| | Blood Glucose | 4 | 2013 | 2330 | 0.090 |
Why?
| | Glucose Intolerance | 1 | 2013 | 142 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 138 | 0.090 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 888 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 341 | 0.080 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2017 | 543 | 0.080 |
Why?
| | Fatty Acids | 1 | 2014 | 452 | 0.080 |
Why?
| | Abdominal Fat | 1 | 2011 | 50 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5417 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 758 | 0.080 |
Why?
| | Signal Transduction | 6 | 2016 | 5233 | 0.080 |
Why?
| | Organ Specificity | 1 | 2011 | 313 | 0.080 |
Why?
| | Recovery of Function | 1 | 2015 | 710 | 0.080 |
Why?
| | Dyslipidemias | 1 | 2012 | 182 | 0.080 |
Why?
| | Risk Assessment | 2 | 2016 | 3676 | 0.080 |
Why?
| | Chemotaxis | 1 | 2010 | 122 | 0.080 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 358 | 0.080 |
Why?
| | Risk Factors | 9 | 2018 | 10792 | 0.080 |
Why?
| | Estradiol | 1 | 2013 | 533 | 0.080 |
Why?
| | NF-kappa B | 2 | 2023 | 662 | 0.080 |
Why?
| | RNA | 1 | 2016 | 940 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2540 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2015 | 685 | 0.070 |
Why?
| | Norepinephrine | 1 | 2009 | 196 | 0.070 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 302 | 0.070 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 110 | 0.070 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.070 |
Why?
| | Enzyme Inhibitors | 4 | 2017 | 826 | 0.070 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 32 | 0.070 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 62 | 0.070 |
Why?
| | Carotid Arteries | 2 | 2024 | 207 | 0.070 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 33 | 0.070 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 14 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 420 | 0.070 |
Why?
| | Cell Line | 2 | 2025 | 2882 | 0.070 |
Why?
| | Organ Size | 2 | 2006 | 463 | 0.060 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 165 | 0.060 |
Why?
| | Substance P | 2 | 2008 | 39 | 0.060 |
Why?
| | Superoxide Dismutase-1 | 1 | 2026 | 10 | 0.060 |
Why?
| | Adult Stem Cells | 1 | 2006 | 39 | 0.060 |
Why?
| | Protein Isoforms | 2 | 2025 | 402 | 0.060 |
Why?
| | United States | 3 | 2020 | 15988 | 0.060 |
Why?
| | Physical Conditioning, Animal | 2 | 2006 | 243 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2026 | 8279 | 0.060 |
Why?
| | Hypertrophy | 2 | 2023 | 127 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2017 | 6434 | 0.060 |
Why?
| | Bone Density | 1 | 2010 | 482 | 0.060 |
Why?
| | Catalase | 1 | 2026 | 130 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2019 | 1173 | 0.060 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 6 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1786 | 0.060 |
Why?
| | Colony-Forming Units Assay | 3 | 2014 | 95 | 0.060 |
Why?
| | Mitochondrial Membranes | 1 | 2025 | 40 | 0.060 |
Why?
| | DNA Methylation | 1 | 2010 | 683 | 0.050 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 285 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2014 | 557 | 0.050 |
Why?
| | 3' Untranslated Regions | 1 | 2025 | 152 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2022 | 17101 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2026 | 301 | 0.050 |
Why?
| | Triglycerides | 2 | 2005 | 521 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 439 | 0.050 |
Why?
| | Diacetyl | 1 | 2003 | 7 | 0.050 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 15 | 0.050 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 12 | 0.050 |
Why?
| | Quadriplegia | 1 | 2023 | 14 | 0.050 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 161 | 0.050 |
Why?
| | Pulse Wave Analysis | 1 | 2024 | 266 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3154 | 0.050 |
Why?
| | Actinin | 1 | 2023 | 12 | 0.050 |
Why?
| | von Willebrand Factor | 1 | 2023 | 85 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2026 | 621 | 0.050 |
Why?
| | Thrombophilia | 1 | 2023 | 88 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2023 | 108 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 28 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 65 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 44 | 0.050 |
Why?
| | Cyclic AMP | 2 | 2014 | 209 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2017 | 276 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 2114 | 0.050 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 37 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 252 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1982 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1496 | 0.040 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 93 | 0.040 |
Why?
| | Premenopause | 1 | 2002 | 123 | 0.040 |
Why?
| | Endopeptidase K | 1 | 2021 | 18 | 0.040 |
Why?
| | Inflammation | 2 | 2019 | 2880 | 0.040 |
Why?
| | Ribonucleases | 1 | 2021 | 49 | 0.040 |
Why?
| | Vital Capacity | 1 | 2002 | 290 | 0.040 |
Why?
| | Serum Response Factor | 1 | 2021 | 33 | 0.040 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 126 | 0.040 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 134 | 0.040 |
Why?
| | Lymphocyte Count | 2 | 2011 | 164 | 0.040 |
Why?
| | Oxygen Consumption | 3 | 2012 | 724 | 0.040 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 54 | 0.040 |
Why?
| | Endothelins | 1 | 2021 | 63 | 0.040 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 37 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 783 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 95 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2002 | 251 | 0.040 |
Why?
| | Cytochromes c | 2 | 2010 | 53 | 0.040 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 86 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 479 | 0.040 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 89 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2499 | 0.040 |
Why?
| | Chronic Disease | 1 | 2025 | 1813 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 936 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 226 | 0.040 |
Why?
| | HIV Antibodies | 1 | 2019 | 60 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 442 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 423 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 744 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 549 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 35 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 212 | 0.040 |
Why?
| | Telomerase | 2 | 2011 | 248 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 460 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2014 | 5997 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 636 | 0.030 |
Why?
| | Electrocardiography | 1 | 2021 | 663 | 0.030 |
Why?
| | Disease Progression | 1 | 2006 | 2852 | 0.030 |
Why?
| | Outpatients | 1 | 2021 | 443 | 0.030 |
Why?
| | Freezing | 1 | 2018 | 86 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 245 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2025 | 2050 | 0.030 |
Why?
| | Fasting | 2 | 2013 | 277 | 0.030 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 19 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 92 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.030 |
Why?
| | Galectin 3 | 1 | 2016 | 21 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 331 | 0.030 |
Why?
| | Electron Transport | 1 | 2016 | 118 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 78 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1268 | 0.030 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 19 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 178 | 0.030 |
Why?
| | Drug Discovery | 1 | 2016 | 155 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 191 | 0.030 |
Why?
| | Myogenic Regulatory Factors | 2 | 2006 | 45 | 0.030 |
Why?
| | MEF2 Transcription Factors | 2 | 2006 | 51 | 0.030 |
Why?
| | Cardiomegaly, Exercise-Induced | 1 | 2014 | 3 | 0.030 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2014 | 32 | 0.030 |
Why?
| | Caseins | 1 | 2014 | 20 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 407 | 0.030 |
Why?
| | Interleukin-18 | 2 | 2006 | 235 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 489 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2884 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 4099 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 103 | 0.030 |
Why?
| | Colorado | 2 | 2016 | 4564 | 0.030 |
Why?
| | Heart Conduction System | 1 | 2014 | 95 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 178 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 125 | 0.020 |
Why?
| | Algorithms | 1 | 2021 | 1839 | 0.020 |
Why?
| | Cross-Over Studies | 2 | 2008 | 601 | 0.020 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 191 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 2014 | 195 | 0.020 |
Why?
| | Ventricular Myosins | 2 | 2003 | 39 | 0.020 |
Why?
| | ROC Curve | 1 | 2015 | 615 | 0.020 |
Why?
| | Interleukin-1 | 1 | 2016 | 961 | 0.020 |
Why?
| | Genistein | 1 | 2012 | 13 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 551 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 851 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 168 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 111 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 162 | 0.020 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 8 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2012 | 200 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 196 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 434 | 0.020 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 46 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2006 | 1217 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 117 | 0.020 |
Why?
| | Waist Circumference | 1 | 2011 | 139 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 848 | 0.020 |
Why?
| | Anthropometry | 1 | 2011 | 200 | 0.020 |
Why?
| | Cardiomyopathies | 1 | 2014 | 338 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 187 | 0.020 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.020 |
Why?
| | Staurosporine | 1 | 2010 | 22 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 89 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 200 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 307 | 0.020 |
Why?
| | Phenotype | 2 | 2011 | 3164 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 381 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 437 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 1003 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 770 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7997 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2008 | 50 | 0.020 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 49 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2836 | 0.020 |
Why?
| | Arm | 1 | 2007 | 110 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2007 | 136 | 0.020 |
Why?
| | Probability | 1 | 2007 | 312 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 119 | 0.010 |
Why?
| | Computational Biology | 1 | 2011 | 681 | 0.010 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2006 | 72 | 0.010 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2006 | 81 | 0.010 |
Why?
| | Thymidine | 1 | 2005 | 60 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2006 | 93 | 0.010 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2006 | 145 | 0.010 |
Why?
| | Caspases | 1 | 2006 | 232 | 0.010 |
Why?
| | Glycogen | 1 | 2004 | 54 | 0.010 |
Why?
| | Calmodulin | 1 | 2004 | 70 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 125 | 0.010 |
Why?
| | Thrombosis | 1 | 2007 | 393 | 0.010 |
Why?
| | Sarcomeres | 1 | 2003 | 98 | 0.010 |
Why?
| | Diastole | 1 | 2003 | 143 | 0.010 |
Why?
| | Cholesterol | 1 | 2005 | 408 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2003 | 415 | 0.010 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 30 | 0.010 |
Why?
| | Physical Education and Training | 1 | 2003 | 71 | 0.010 |
Why?
| | Adenine | 1 | 2005 | 339 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2003 | 304 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 612 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 88 | 0.010 |
Why?
| | Vascular Patency | 1 | 2002 | 121 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 158 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 2002 | 299 | 0.010 |
Why?
| | Models, Animal | 1 | 2003 | 392 | 0.010 |
Why?
| | Potassium | 1 | 2002 | 152 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2003 | 340 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 169 | 0.010 |
Why?
| | Progesterone | 1 | 2003 | 255 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1048 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 392 | 0.010 |
Why?
| | Life Style | 1 | 2003 | 479 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1500 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 5965 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1742 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1241 | 0.010 |
Why?
| | Insulin | 1 | 2005 | 2507 | 0.010 |
Why?
|
|
Stauffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|